Sign in
ALVO Stock Price, Chart, Stats & News
Alvotech
Save
Alvotech (ALVO) does not currently pay a dividend.
1.94B
Market cap
–
Current P/E
15.24x
Forward P/E
ALVO chart
Fundamentals
Gross margin | 55.42% |
Operating margin | 7.61% |
Pretax margin | 9.15% |
Net margin | 12.17% |
Effective tax rate | -33.05% |
ROA | 4.93% |
ROE | -26.11% |
D/E | -7.25x |
Interest coverage ratio | -0.86x |
ALVO valuation
P/E | – |
P/S | 1.70x |
P/B | -5.28x |
P/CF | -35.26x |
P/FCF | -8.54x |
P/OCF | -35.26x |
PEG | 1.61x |
EV multiple | -3.72x |
About
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira.
Similar securities
Based on sector and market capitalization
Report issue